EpCAM+ or HER2/neu+: > 10% stained cells in autologous tumor cell preparations; CUP = carcinoma of unknown primary. Application of trAb and monitoring All nine patients received i.p. trAb applications. No dose escalation for the third application was performed in www.selleckchem.com/products/pnd-1186-vs-4718.html patient A because of side effects. In patient C, reduced starting dose of 5 μg was in respect of a body weight of 43 kg only; Patient F refused the third application of trAb. For detailed

therapy of each patient, please see Table 2 and Table 3. Table 2 I.p. application of trAb CP673451 in vivo anti-EpCAM and side effects Pat. TrAb anti-EpCAM therapy (μg i.p./day) Cumulative dose Side effects   μg day μg day μg day (μg)   A 10 1 20 5 20 9 50 Elev. of AP (3), γ-GT (4); fever (3); abdominal pain (3); vomiting (3) B 10 1 20 6 40 9 70 Elev. of AP (2), bilirubin (2), γ-GT (3), GOT (3), GPT (3); fever (3); abd. pain (3); vomiting (2); allergic exanthema OICR-9429 (2) C 5 1 20 3 40 7 65 Fever (2) F 10 1 20 5 –   30 Elev. of AP (2), PTT (2), GPT (3); fever (1); abdominal pain (3); vomiting (2) G 10 1 20 5 40 10 70 Elev. of AP (1), bilirubin (2), γ-GT (3), GPT (3); fever (1); abdominal pain (3) H 10 1 20 7 40 13 70 Elev. of AP (1), bilirubin (2), gGT (3), creatinine (2); fever (1); abdominal pain (3) I 10 1 20 8 40 12 70 Elev. of AP (1); fever (2); vomiting (3) Table 3 I.p. application

of trAb anti-Her2/neu and side effects Pat. TrAb anti Her2/neu therapy (μg i.p./day) Cumulative dose Side effects   μg Day μg Day μg day (μg)   D 10 1 40 4 80 8 130 Fever (1) E 10 1 40 6 80 8 130 Fever (1); abdominal pain (2) Individual schedule of trAb therapy and side effects according to the National Cancer Institute (NCI) common toxicity criteria. TrAb treatment was accompanied by transient fever (up to 40.4°C) after 9 applications. The fever developed

six to ten hours after trAb infusion and disappeared within the next day. Metamizole (1000 mg) was given in these cases. Six patients complained about abdominal pain; four patients had vomiting and required treatment with Dimenhydrinate. No patient required ICU admittance. Atezolizumab supplier Elevated liver enzymes, elevated levels of γ-glutamyl transferase and alkaline phosphatase were observed after trAb application. These laboratory changes disappeared spontaneously within the treatment intervals. TrAb treatment was followed by an elevation of serum levels of IL-6, TNF-α, and soluble IL-2 receptor one day after treatment. The slight decrease on the second day after every trAb application was statistically not significant (Figure 1A, 1B). The inflammatory cytokine IL-6 showed a substantial increase after the first trAb infusion only; despite trAb dose escalation there were only moderate increases after the following two applications (Figure 1C).